Lombard Odier Asset Management (Usa) Corp Glaukos Corp Transaction History

Lombard Odier Asset Management (Usa) Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$58.58 - $83.91 $1.76 Million - $2.52 Million	-30,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$63.59 - $78.71 $1.46 Million - $1.81 Million	23,000 Added 328.57%	30,000 $2.26 Million
Q1 2019 May 15, 2019	SELL	$50.75 - $80.54 $1.93 Million - $3.06 Million	-38,000 Reduced 84.44%	7,000 $549,000
Q4 2018 Feb 14, 2019	BUY	$52.18 - $67.93 $1.57 Million - $2.04 Million	30,000 Added 200.0%	45,000 $2.53 Million
Q3 2018 Nov 14, 2018	SELL	$38.13 - $68.37 $800,730 - $1.44 Million	-21,000 Reduced 58.33%	15,000 $974,000
Q2 2018 Aug 14, 2018	BUY	$27.62 - $44.51 $994,320 - $1.6 Million	36,000 New	36,000 $1.46 Million
Q4 2017 Feb 13, 2018	SELL	$24.5 - $36.01 $3.88 Million - $5.7 Million	-158,387 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$31.26 - $42.03 $4.95 Million - $6.66 Million	158,387	158,387 $5.23 Million

345

46.7M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.63B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Usa) Corp, based on Form 13F filings with the SEC.

Stay updated on Lombard Odier Asset Management (Usa) Corp with notifications on news.